• For diabetic macular edema (DME)
  • For macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
  • For noninfectious posterior segment uveitis

Ozurdex® targets multiple inflammatory cytokines

  • OZURDEX® is a sustained-release, biodegradable steroid implant containing dexamethasone, a corticosteroid4
  • Dexamethasone has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines, resulting in decreased4:
  • Edema
  • Fibrin deposition
  • Capillary leakage
  • Migration of inflammatory cells

see how ozurdex® works to treat Diabetic Macular Edema (DME)


see how ozurdex® works to treat macular edema following RVO (BRVO or CRVO)

how ozurdex® works in noninfectious posterior segment uveitis

  • Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells4
  • In noninfectious posterior segment uveitis, evidence suggests that inhibition of the cytokine NF-kB plays a key role in suppression of inflammation7

novadur® technology:
a proprietary drug delivery system

  • A sustained-release, biodegradable steroid implant4
  • Solid polymer matrix contains 0.7 mg of dexamethasone, a corticosteroid4
  • Biodegrades to lactic acid and glycolic acid4
  • Administered by injection as an in-office procedure4
3 weeks
after implantation
Scanning electron microscopy (SEM) magnification of implant surface in an animal model. Clinical significance unknown.3

A patented
intravitreal applicator

  • Sterile, single-use applicators are supplied preloaded with an implant4
  • Includes second-generation needle
  • Implants are administered using a shelved injection technique4

See how the ozurdex® applicator works

Click here to access injection technique educational resources.

help patients learn more about ozurdex® for their condition